Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2026)

Beam Therapeutics (BEAM) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 0.95% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 13.21% YoY), while the FY2025 annual figure was $1.5 billion, up 34.19% from the prior year.
• Liabilities and Shareholders Equity steadied at $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2025 and bottomed at $1.1 billion in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 109.65% — and 2024, when it retreated 24.38%.
• Beam Therapeutics' Liabilities and Shareholders Equity stood at $1.3 billion in 2022, then gained by 8.79% to $1.5 billion in 2023, then decreased by 24.38% to $1.1 billion in 2024, then jumped by 34.19% to $1.5 billion in 2025, then dropped by 0.03% to $1.5 billion in 2026.
• Business Quant data shows BEAM's Liabilities and Shareholders Equity at $1.5 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.3 billion in Q3 2025.